| | Over a decade in the making, CAR T-Cell Therapy has proven to be one of the more innovative and promising treatments in oncology. Learn more about what companies should consider when it comes to this cutting edge treatment from a free white paper by TD2. |
GSK culls a host of pipeline meds after failures, prioritization Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout Sanofi pulls out of late-phase Daiichi vaccine collaboration Sponsored: FROM CHOLERA TO COVID-19: How integrated data visualizations inform decisions and impact actions Roche bets $120M on UCB’s anti-tau Alzheimer’s antibody ExeVir bags €23M to take llama-derived COVID-19 drug into clinic 'Genome-tuning' biotech Omega Therapeutics snags $85M as it aims for the clinic Nura Bio uncloaks with $73M and Biogen vet Alpna Seth as CEO Thrive flourishes, raises $257M to carry forward its cancer-seeking blood test Tackling diabetes with an oral drug that blocks a glucose-induced gene Roche arthritis drug Actemra flunks COVID-19 study, but remdesivir combo data await Featured Story | By Ben Adams GlaxoSmithKline is making headlines for its COVID-19 vaccine work, but it has quietly swept away a series of pipeline assets amid its quarterly results posted Wednesday morning. read more |
| |
|---|
|
Top Stories By Ben Adams Amgen has culled a bispecific drug it picked up in a $1.7 billion biobucks deal with Xencor. read more By Nick Paul Taylor Sanofi has pulled out of a pediatric pentavalent vaccine collaboration with Daiichi Sankyo in Japan. The action, which Sanofi disclosed alongside other pipeline updates, follows a multiyear effort to get phase 3 data on the vaccine candidate. read more By PerkinElmer, Inc How integrated data visualizations inform decisions and impact actions. Data visualization was first used to recognize disease patterns in the 1854 London cholera outbreak. It is even more essential today. read more By Amirah Al Idrus As Roche plugs away at its anti-amyloid treatment for Alzheimer’s disease, it’s adding a tau-targeting treatment to the mix. The Swiss pharma is handing over $120 million upfront for the right to develop UCB’s anti-tau antibody. If all goes to plan, milestone payments and royalties could bring the deal’s total close to $2 billion. read more By Nick Paul Taylor ExeVir Bio has raised €23 million ($27 million) to advance a llama-derived antibody against COVID-19. The financing, which attracted the support of Fund+ and UCB, follows research showing an approach similar to that used by Ablynx can yield single-domain antibodiesthat neutralize SARS-CoV-2. read more By Amirah Al Idrus Omega Therapeutics' $85 million cash boost will push a pipeline of treatments toward the clinic as well as bankroll the identification of new targets for genomic medicines. Rather than switching genes on and off, cutting out disease-causing genes or replacing them with healthy versions, Omega’s platform is designed to “tune” gene expression to healthy levels. read more By Amirah Al Idrus Alpna Seth, the Biogen veteran who ushered Tecfidera from the clinic to commercial launch, is back in the neuro space. After a couple of years at Vir Biotechnology, she’s taking the wheel at Nura Bio, a company working on neuroprotective drugs that could be useful for a range of conditions from amyotrophic lateral sclerosis (ALS) to Alzheimer’s disease. read more By Conor Hale Thrive Earlier Detection has drawn a substantial $257 million in its second venture capital round to help push its multi-cancer blood test through clinical trials toward FDA approval. read more By Arlene Weintraub Researchers at the University of Alabama at Birmingham reported that a small-molecule drug candidate normalized blood glucose in rodent models of severe Type 2 diabetes and prevented mice from developing a form of Type 1 diabetes. The drug controls TXNIP, a protein that can destroy insulin-producing beta cells in the pancreas. read more By Angus Liu Yet another attempt at repurposing existing drugs for COVID-19 appears to have failed. Roche said its arthritis med Actemra didn't top placebo at improving clinical status among patients with severe COVID-19 pneumonia, but the company is still counting on a combination with Gilead's remdesivir. read more Resources Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. Sponsored by: Cambrex The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet. Sponsored by: EVERSANA How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.” Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 